Observed Signal · Nov 16, 2026 · Regulatory Milestone · Source: PR Newswire: Advertising & Marketing · Impact: 2/5 · Sentiment: Positive

Fortvita Biologics Gets First Positive CHMP Opinion for Zybrivo

Executive Signal Summary

Fortvita Biologics, a member of the Innovent Group, announced its first positive opinion from the European Medicines Agency's CHMP. The opinion recommends marketing authorization for Zybrivo (sintilimab) in combination with chemotherapy for the first-line treatment of adults with advanced non-squamous non-small cell lung cancer. If approved by the European Commission, Zybrivo would be available across all 27 EU member states plus Iceland, Norway, and Liechtenstein. The recommendation is based on the Phase 3 ORIENT-11 study, which showed a 52% reduction in the hazard of disease progression or death and a 35% reduction in the hazard of death versus placebo plus chemotherapy. Fortvita is strengthening its capabilities for European market access. This is the first medicine in Fortvita's globalization strategy beyond China.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

This is a significant regulatory milestone for Fortvita and Innovent, potentially expanding lung cancer treatment options in Europe, but it is not directly relevant to the AdTech, MarTech, or advertising industry.

MARKET SIGNALS

Track Biotech Signals & Market Shifts

Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.

  • Verified primary sources
  • Automated briefings
  • Instant watchlist setup

Key Takeaways & Evidence Grounding

  • Fortvita Biologics received its first positive CHMP opinion from the European Medicines Agency for Zybrivo (sintilimab).
  • The CHMP recommends marketing authorization for Zybrivo in combination with chemotherapy for first-line treatment of advanced non-squamous non-small cell lung cancer.
  • The European Commission is expected to issue a final decision on marketing authorization in the coming months.
  • The positive opinion is based on results from the Phase 3 ORIENT-11 study, which showed a 52% reduction in the hazard of disease progression or death and a 35% reduction in the hazard of death.
  • Sintilimab has been used to treat approximately 3 million patients in China.
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: PR Newswire: Advertising & Marketing•Published: Nov 16, 2026
Original Coverage Title: “Fortvita Receives Its First Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer”

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

Product & Platform LaunchSep 11, 2026

New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026

Johnson & Johnson announced new overall survival data and treatment experience improvements for RYBREVANT-based regimens in EGFR-mutated lung cancer at WCLC 2026. Final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC will be featured in a Presidential Symposium. Additional findings show low rates of key treatment-related events with subcutaneous RYBREVANT FASPRO and prophylactic strategies.

Read assessment
BiotechOct 23, 2026

Intensity Therapeutics Presents INVINCIBLE-4 TNBC Data

Intensity Therapeutics announced that data from the first seven patients in Cohort A of the INVINCIBLE-4 study will be presented at the ESMO 2026 congress. The study evaluates INT230-6, an intratumoral therapy, in combination with neoadjuvant immunochemotherapy (NAIC) for early-stage triple-negative breast cancer (TNBC). Results showed a pathological complete response (pCR) in the breast and lymph nodes in 5 of 7 patients (71%). No invasive cancer cells in axillary lymph nodes were detected in 6 of 7 patients, despite 71% being initially node-positive. Tumor necrosis was observed in all patients after 1-2 injections. Adverse events were low grade, with dose-limiting skin reactions. The data suggest potential efficacy of INT230-6 in this setting.

Read assessment
Regulatory ApprovalOct 23, 2026

China Approves Harbour BioMed's Batoclimab for gMG

Harbour BioMed announced that China's NMPA has approved its Biologics License Application for batoclimab SC, a subcutaneous anti-FcRn therapy, for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-AChR antibody positive. Approval was supported by a pivotal Phase 3 study in 27 Chinese centers showing significant improvements in primary and secondary endpoints. Batoclimab SC was generally well tolerated, with peripheral edema as the most common adverse event. Commercialization in Greater China will be conducted by NBP Pharma, a subsidiary of CSPC Pharmaceutical Group, under a license agreement, with Harbour BioMed receiving tiered royalties. Batoclimab was originally developed by HanAll Biopharma and licensed to Harbour BioMed in 2017.

Read assessment

WATCHLIST & BRIEFINGS

Receive future signals for Biotech in your Watchlist briefing

Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.

  • Regular primary-source checks
  • Structured Watchlist briefings
  • Preserves current context